Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy Gleason score, and clinical T-stage

International Journal of Radiation Oncology Biology Physics

Volumn 45, Issue 5, 1999, Pages 1227-1233

  D'Amico, Anthony V ^a   Whittington, Richard ^b   Malkowicz, S Bruce ^b   Schultz, Delray ^c   Renshaw, Andrew A ^d   Tomaszewski, John E ^b   Richie, Jerome P ^d   Wein, Alan ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c University of Millersville   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

3D conformal dose escalation; Implant boost; Patient selection; Prostate cancer; Prostate specific antigen

Indexed keywords

ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DOSE CALCULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TREATMENT OUTCOME; TREATMENT PLANNING;

BIOPSY; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PATIENT SELECTION; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REGRESSION ANALYSIS;

EID: 0032785005     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(99)00303-X     Document Type: Article

References (16)

1. Iselin C.E., Robertson J.E., Paulson D.F. Radical perineal prostatectomy Oncological outcome during a 20-year period . J Urol. 161:1999;163-168.
2. Walsh P.C., Partin A.W., Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy Results at 10 years . J Urol. 152:1994;1831-1836.
3. Gleason D.F. Histologic grading and staging of prostatic carcinoma. Tannenbaum M. Urologic pathology. 1977;171-187 Lea & Febiger, Philadelphia.
4. Beahrs O.H., Henson D.E., Hutter R.V.P. American Joint Committee on Cancer, Manual for staging cancer, 4th ed. 1992;J.P. Lippincott, Philadelphia.
5. Oesterling J.E., Jacobsen S.J., Klee G.G., et al. Free, complexed and total serum prostate specific antigen The establishment of appropriate reference ranges for their concentrations and ratios . J Urol. 154:1995;1090-1095.
6. Simultaneous inferences and other topics in regression analysis-1. In: Neter J, Wasserman W, Kutner M, editors. Applied linear regression models, 1st ed. Homewood, IL: Richard D. Irwin, Inc; 1983. p. 150-153.
7. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Amer Stat Assoc. 53:1958;457-500.
8. Hanks G.E., Hanlon A.L., Horwitz E., Pinover W., Schultheiss T. A relationship of local prostate dose and subsequent metastasis with 3D CRT in prostate cancer (Abstract 38). Int J Radiat Oncol Biol Phys. 42S:1998;143.
9. Fiveash J.B., Hanks G.E., Roach M. III, Wang S., Vigneault E., McLaughlin W., Sandler H.M. 3D Conformal radiation therapy (3DCRT) for high grade prostate cancer A multi-institutional review (Abstract 37) . Int J Radiat Oncol Biol Phys. 42S:1998;143.
10. Pinover W., Hanlon A.L., Horwitz E.M., Hanks G.E. Defining the appropriate dose for prostate cancer patients with PSA < 10 ng/ml (Abstract 36). Int J Radiat Oncol Biol Phys. 42S:1998;142.
11. Ragde H., Eigamal A.A., Snow P.B., Brandt J., Bartolucci A.A., Nadir B.S., Korb L.J. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
12. Critz F.A., Levinson K., Williams W.H., Holladay D.A. Prostate-specific antigen nadir The optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2893-2900.
13. Beard C.J., Kijewki P., Bussiere M., Gelman R., Gladstone D., Shaffer K., Plunkett M., Costello P., Coleman C.N. Analysis of prostate and seminal vesicle motion Implications for treatment planning . Int J Radiat Oncol Biol Phys. 34:1996;451-458.
14. Bolla M., Gonsalez D., Warde P., Dubois J.B., Mirimanoff R., Storme G., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med. 337:1997;295-300.
15. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Tomaszewski J.E., Kaplan I., Beard C., Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc. 280:1998;969-974.
16. Keyser D., Kupelian P.A., Zippe C.D., Levin H.S., Klein E.A. Stage T1-2 prostate cancer with pre-treatment prostate-specific antigen level ≤ 10 ng/ml Radiation therapy or surgery? Int J Radiat Oncol Biol Phys. 38:1997;723-729.